PHIO Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 22:59):

Stats
Šios dienos apimtis	333 976
Vidutinė apimtis	418 350
Rinkos kapitalizacija	3.70M
EPS	$0 ( 2024-04-03 )
Kita pelno data	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.160
ATR14	$0.00500 (0.60%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Kontulis Caitlin	Sell	335	Common stock, $0.0001 par value
2024-02-26	Bitterman Robert J	Buy	2 500	Common stock, $0.0001 par value
2024-02-20	Bitterman Robert J	Sell	1 804	Common stock, $0.0001 par value
2024-02-15	Kontulis Caitlin	Sell	658	Common stock, $0.0001 par value
2024-02-17	Kontulis Caitlin	Sell	523	Common stock, $0.0001 par value

INSIDER POWER
77.00
Last 97 transactions
Buy: 3 139 429 \| Sell: 140 691

Tūris Koreliacija

Ilgas: -0.14 (neutral)

Trumpas: -0.16 (neutral)

Signal:(62.156) Neutral

Phio Pharmaceuticals Corp Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Phio Pharmaceuticals Corp Koreliacija - Valiuta/Žaliavos

-0.46
( neutral )

-0.47
( neutral )

0.00
( neutral )

-0.32
( neutral )

0.74
( moderate )

0.40
( neutral )

Phio Pharmaceuticals Corp Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-184 000 (0.00 %)
EPS:	$-5.20

FY	2023
Pajamos:	$0
Bruto pelnas:	$-184 000 (0.00 %)
EPS:	$-5.20

FY	2022
Pajamos:	$0
Bruto pelnas:	$-193 000 (0.00 %)
EPS:	$-9.95

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-12.43

Financial Reports:

No articles found.

Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.